---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000006"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T09:55:29.364535+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine restructures Takeda deal for osavampator; gets global rights ex-Japan

## Summary
- Neurocrine obtains exclusive worldwide development/commercialisation rights for osavampator except Japan, converts from profit-sharing to royalty-bearing license.
- Takeda reacquires exclusive rights in Japan; royalties payable by each party on net sales in other's territory.
- Tiered royalties to Takeda: mid-to-upper teens (US), low double-digits (ex-US) as % of net sales.
- Phase 3 program for major depressive disorder expected to start H1 2025 after successful End-of-Phase 2 FDA meeting.
- Amended agreement dated January 24, 2025; press release issued January 27, 2025.

## SEC filing metadata
- accession: 0000914475-25-000006
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/0000914475-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000006/nbix-20250124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000006
- JSON: https://secwatch.observer/filing/0000914475-25-000006.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.